Skip to main content

Abstract

Objective:

Kraepelin considered declining course a hallmark of schizophrenia, but others have suggested that outcomes usually stabilize or improve after treatment initiation. The authors investigated this question in an epidemiologically defined cohort with psychotic disorders followed for 20 years after first hospitalization.

Method:

The Suffolk County Mental Health Project recruited first-admission patients with psychosis from all inpatient units of Suffolk County, New York (response rate, 72%). Participants were assessed in person six times over two decades; 373 completed the 20-year follow-up (68% of survivors); 175 had schizophrenia/schizoaffective disorder. Global Assessment of Functioning (GAF), psychotic symptoms, and mood symptoms were rated at each assessment. Month 6, when nearly all participants were discharged from the index hospitalization, was used as a reference.

Results:

In the schizophrenia group, mean GAF scores declined from 49 at month 6 to 36 at year 20. Negative and positive symptoms also worsened (Cohen’s d values, 0.45–0.73). Among participants without schizophrenia, GAF scores were higher initially (a mean of approximately 64) but declined by 9 points over the follow-up period. Worsening began between years 5 and 8. Neither aging nor changes in antipsychotic treatment accounted for the declines. In all disorders, depression improved and manic symptoms remained low across the 20 years.

Conclusions:

The authors found substantial symptom burden across disorders that increased with time and ultimately may undo initial treatment gains. Previous studies have suggested that better health care delivery models may preempt this decline. In the United States, these care needs are often not met, and addressing them is an urgent priority.
Emil Kraepelin (1) considered declining course a distinguishing feature of schizophrenia (dementia praecox) in contrast to the nondeclining, episodic course of mood disorders with psychosis. Others have challenged this view, suggesting that a downward trajectory is not typical of schizophrenia and that outcomes tend to improve over time (2, 3). Prospective investigations of clinical course—evolution of symptom burden over time—in first-episode or first-admission psychosis can provide key evidence for answering this question, as they employ a well-defined early starting point.
Numerous studies have followed first-episode psychosis cohorts in the short and medium terms. A systematic review (4) found global outcome to be fairly stable across the first decade of illness. Recent 10-year follow-up studies of two seminal first-episode cohorts found that positive symptoms initially improve and then stabilize, while negative symptoms remain largely unchanged (5) and only a minority of participants are continuously ill (6). Overall, this research did not suggest a decline in the first decade of illness, but the second decade may be different.
The international Determinants of Outcome of Severe Mental Disorders (DOSMeD) project is, to date, the only prospective study to have followed first-episode patients for two decades (7, 8). More than half of participants with schizophrenia had good outcome (defined as a Global Assessment of Functioning [GAF] score >60), and 50% improved over the interval, whereas only 23% declined (8). However, limited interim information precluded charting of illness trajectories. Also, these analyses included only one small sample (N=56) from the United States, and large cross-national differences in outcomes were observed (8). The most similar U.S. project, the Chicago Follow-Up Study, assessed an early-course sample six times over two decades after admission with psychosis. In participants with schizophrenia, global outcome improved through year 7.5 and then stabilized, with about 20% having good outcomes (9). Repeated assessments provided a detailed picture of illness course, but conclusions are limited by a sample drawn primarily from a private hospital.
Less is known about the long-term course of mood disorders with psychosis. The DOSMeD study did not analyze this group separately but presented all participants with nonschizophrenia psychoses together and found better outcomes (two-thirds had GAF scores >60) and course (69% improving and only 12% declining) than in the schizophrenia group (8). In the Chicago Follow-Up Study, nonschizophrenia psychoses also had a better course, with global outcomes improving through year 4.5 and then stabilizing, with about 40% of participants having good outcomes (9). Another investigation (6) found that only 8% of patients with psychotic mood disorders were continuously ill during the decade after first admission. To our knowledge, no study has charted the illness trajectories of this group over 20 years.
Previous long-term studies have focused largely on global outcome and overall pattern of course. Consequently, trajectories of specific symptoms are less understood. At least four clearly distinct dimensions of psychotic symptoms have been identified: reality distortion (i.e., hallucinations, delusions), disorganization, inexpressivity, and apathy-asociality (10, 11). This scheme is an elaboration of the classic three-dimensional model (12) through division of negative symptoms into apathy-asociality and inexpressivity. Mood symptoms—depression and mania—also play a prominent role in psychotic disorders (13, 14). These six dimensions follow distinct trajectories (15), yet long-term data on changes in many of these symptoms over time are lacking.
We sought to address the aforementioned limitations of long-term follow-up studies of clinical course by 1) examining an epidemiologically defined first-admission psychosis cohort, 2) tracing trajectories of the six symptom dimensions as well as global outcome (GAF) across two decades, 3) following a sufficiently large group of patients with psychotic mood disorders to chart their course precisely and compare it with the course of schizophrenia, and 4) using longitudinal consensus diagnoses to define study groups with high accuracy. To our knowledge, this is the first study to put the four techniques together, offering an unprecedented opportunity to clarify the disagreement between modern views of illness course and Kraepelin’s descriptions. Moreover, this also is the first study to attempt direct replication of DOSMeD’s long-term findings in the United States.

Method

Participants

The cohort was assembled by the Suffolk County Mental Health Project, an epidemiologic study of first-admission psychosis (11, 16, 17). Participants were recruited from the 12 psychiatric inpatient units of Suffolk County, New York, between 1990 and 1995. Inclusion criteria were first admission either current or within 6 months, clinical evidence of psychosis, ages 15–60, IQ >70, proficiency with English, residency in Suffolk County, and no apparent medical etiology for the psychosis. The study was approved annually by the institutional review boards of Stony Brook University and the participating hospitals.
We initially interviewed 675 participants (72% of referrals); 628 of them met the eligibility criteria. Follow-ups were conducted at 6 months, 24 months, 48 months, 10 years, and 20 years. Seventy-nine participants died during the 20 years. Of the 549 survivors, 373 were successfully contacted at year 20 and constitute the analysis sample. Of these, 68.9% lived in Suffolk County, 6.4% moved to another county in New York, and 24.7% moved to another state. Surviving nonparticipants—patients who completed baseline assessment but did not participate in the 20-year follow-up assessments and were not known to be deceased (N=176)—were similar to the analysis sample on baseline study variables (demographic characteristics, diagnosis, and symptoms) (Table 1), but they were less likely to be Caucasian (67.6% compared with 77.7%) and on average had more severe reality distortion symptoms (Cohen’s d=0.23). For the analysis sample (N=373), we had 2,046 observations across six waves (i.e., the data were 91.4% complete). Follow-ups that were done over the telephone (277 across the six waves) did not allow the behavioral ratings necessary for scoring inexpressivity, resulting in 1,769 observations available for inexpressivity. The primary analyses employed maximum likelihood estimation and thus used all available data.
TABLE 1. Baseline Characteristics of the Follow-Up Cohort and Surviving Nonparticipants in a Study of Psychotic Disorders Over the Two Decades Following First Hospitalizationa
MeasureFollow-Up Cohort (N=373)Nonparticipants (N=176)
Demographic characteristicsN%N%
Male22259.59755.1
Age <28 years19552.38749.4
Blue-collar household16544.27542.6
Caucasianb29077.711967.6
Research diagnosis (last available)    
 Schizophrenia spectrum disorder17546.97341.5
 Bipolar I disorder with psychosis9425.24123.3
 Major depressive disorder with psychosis4311.52514.2
 Substance-induced psychosis256.7169.1
 Other/undetermined psychosis369.72111.9
Baseline ratingsMeanSDMeanSD
GAF (best month in year before hospitalization)58.1714.2559.9814.87
Apathy-asociality9.387.618.906.21
Inexpressivity7.328.086.286.98
Reality distortionb10.738.7112.7810.39
Disorganization6.896.526.325.89
Depression17.525.3817.224.93
Mania/excitement1.661.161.531.07
a
Surviving nonparticipants were patients who completed the baseline assessment but did not participate in the 20-year follow-up and were not known to be deceased: 78 declined, 70 were lost to follow-up, 15 were impossible to interview (abroad or institutionalized), and 13 provided brief updates that were insufficient for target ratings. There were no significant differences between groups except as otherwise noted. GAF=Global Assessment of Functioning.
b
Significant difference between the follow-up cohort and the surviving nonparticipants (p<0.05).

Measures

Interviews were conducted by master’s-level mental health professionals. Medical records and interviews with significant others were solicited at every assessment. This multisource information was used to complete the following rating scales about past-month symptoms: the Scale for the Assessment of Negative Symptoms (SANS) (18), the Scale for the Assessment of Positive Symptoms (SAPS) (19), the Brief Psychiatric Rating Scale (BPRS) (20), and the Structured Clinical Interview for DSM-III-R (SCID) (21). For the present sample, we scored four reliable factor-analytically derived subscales from the SANS and SAPS: inexpressivity (Cronbach’s alpha≥0.88, nine items), apathy-asociality (alpha≥0.81, six items), reality distortion (alpha≥0.80, 14 items), and disorganization (alpha≥0.72, 11 items) (11). Mania was operationalized with the excitement rating of the BPRS. Depressive symptoms were assessed with the current depression module of the SCID, administered without skip-outs. We constructed a nine-symptom depression composite (score range, 9–27) that has excellent reliability (alpha≥0.81) and validity (11, 17). All ratings were highly reliable (see the Supplemental Methods section in the data supplement that accompanies the online edition of this article).
Primary DSM-IV diagnoses were formulated at the 10-year point by consensus of study psychiatrists using all available information (17). The same process was performed in previous waves, including the 6-month assessment. Diagnoses were grouped into five categories: schizophrenia/schizophreniform/schizoaffective disorder, bipolar disorder with psychosis, depression with psychosis, substance-induced psychosis, and other/undetermined psychosis (e.g., psychotic disorder not otherwise specified). Psychiatrists made consensus ratings of the Global Assessment of Functioning (GAF) for the best month of the year before interview, an index that captures both symptom burden and functional impairment. At year 20, psychiatrists also rated the overall pattern of clinical course, using the DOSMeD criteria (see the Supplemental Methods section in the data supplement) (22). For interpretability, we grouped eight course categories into three: single episode (i.e., baseline episode resolved, no recurrence), multiple episodes, and continuous illness (i.e., no remission).

Data Analysis

We investigated trajectories of each disorder on seven outcome measures: the GAF (primary measure) and the six symptom dimensions. At baseline all participants were highly symptomatic and hospitalized; therefore, baseline could not be included in the model, and we started charting trajectories from month 6. We focus here on mean disorder trajectories. Within-group heterogeneity was reported previously (11).
First, we examined clinical course in bivariate analyses, using paired t tests to compare outcomes at follow-ups subsequent to month 6. We used independent-samples t tests to compare outcomes between disorders. Next, we charted trajectories of disorders across all waves by fitting multilevel spline regression models with a random intercept (see the Supplemental Methods section in the data supplement) (2325). Models were fitted for each disorder separately; they estimated trajectories of individual participants and then calculated the mean trajectory for the group. These analyses took advantage of variation in follow-ups around target dates (i.e., some were done late and others early), which allowed us to chart trajectories through year 23. However, data were limited for years 5–8 and 13–16 (< 20 observations/year), and these portions of the trajectories were estimated less precisely. Spline regression is a piecewise regression that allows different slopes in different segments of the predictor variable. We considered up to three segments (the largest number suggested by descriptive analyses). Transition points between segments were determined empirically by testing the full range of possible transition points and selecting the model with the best Bayesian information criterion (26). The number of segments was determined similarly. Finally, we added age and antipsychotic medication as time-varying covariates to the resulting models to determine whether the observed changes were independent from variation in these covariates.

Results

Description of Clinical Course

Table 2 summarizes the outcomes and antipsychotic medication use of the five diagnostic groups across the two decades. The pattern is notable for worse outcomes in schizophrenia. Differences among the other groups were less pronounced, although the bipolar disorder with psychosis group and the psychotic depression group often had better outcomes than the substance-induced and other/undetermined psychoses groups. Notably, within-group variability was substantial and often dwarfed between-group differences. The overall pattern of clinical course over 20 years indicated that schizophrenia typically followed a chronic course (74.1% of patients continuously ill), whereas an episodic course was common in bipolar disorder with psychosis (79.5%) and psychotic depression (66.7%), and the other two groups fell between them. The psychotic depression, substance-induced psychosis, and other/undetermined groups were too small (Ns <50) for planned analyses; therefore, we combined groups based on similarity of course, resulting in three larger categories: schizophrenia (N=175), mood disorders with psychosis (N=137), and other psychoses (N=61).
TABLE 2. Characteristics of Diagnostic Groups Over Time in a Study of Psychotic Disorders Over the Two Decades Following First Hospitalizationa
Outcome Measure and Assessment PointSchizophreniaBipolar Disorder With PsychosisPsychotic DepressionSubstance-Induced PsychosisOther/Undetermined
 MeanSDMeanSDMeanSDMeanSDMeanSD
GAF          
 Baseline52.6514.1767.839.4460.3012.9957.6811.9257.5314.64
 6 months49.3413.1866.3711.9061.4513.9461.7411.4562.7312.67
 24 months50.3912.9069.1410.8364.9812.3164.6511.4560.9614.39
 48 months49.2712.2170.0511.8167.9312.0365.0513.0663.1315.10
 10 years44.0610.6766.9513.1465.6111.7261.3913.9960.9315.49
 20 years35.7910.5757.7916.7852.8116.0653.8816.8251.3319.03
Apathy-asociality          
 Baseline12.117.364.955.7410.677.608.405.616.868.26
 6 months11.557.925.236.058.517.877.354.985.697.11
 24 months11.316.643.765.206.977.325.875.746.366.90
 48 months11.306.703.704.675.676.884.474.907.677.12
 10 years13.998.143.534.754.605.777.877.966.628.13
 20 years17.568.848.007.7010.118.529.749.0511.5110.23
Inexpressivity          
 Baseline10.228.393.866.106.608.434.285.705.287.23
 6 months10.528.922.644.795.007.093.304.203.926.58
 24 months9.488.191.802.633.685.623.225.142.684.64
 48 months8.828.821.613.152.243.661.533.223.725.30
 10 years7.997.671.683.981.874.152.404.572.836.49
 20 years10.3210.373.695.454.267.134.006.177.9011.34
Reality distortion          
 Baseline12.549.3610.778.876.236.008.406.898.836.05
 6 months4.267.440.561.292.814.561.523.192.504.67
 24 months4.416.360.993.190.922.741.833.663.406.30
 48 months4.036.671.052.780.942.521.533.013.447.96
 10 years6.668.240.461.861.032.291.783.253.075.69
 20 years7.319.340.842.160.932.322.734.793.475.92
Disorganization          
 Baseline7.197.008.976.051.862.965.685.376.896.07
 6 months2.995.141.613.000.891.370.701.152.082.64
 24 months2.994.352.193.931.082.132.093.633.365.22
 48 months3.654.872.344.220.731.860.471.022.333.07
 10 years4.276.001.793.740.942.451.292.243.646.20
 20 years6.167.283.215.222.454.332.073.765.716.32
Depression          
 Baseline17.045.0216.855.1322.215.2316.965.8316.425.10
 6 months13.554.0312.133.3515.515.5112.703.9713.045.08
 24 months13.204.4611.163.4712.865.2712.524.6713.725.00
 48 months10.693.799.943.0712.005.7210.533.4211.725.38
 10 years11.923.7610.993.4713.355.1012.554.2711.373.25
 20 years11.603.2811.873.9313.354.5711.433.5112.453.85
Mania/excitement          
 Baseline1.491.002.131.391.070.341.961.341.781.22
 6 months1.210.661.440.901.000.001.260.751.200.71
 24 months1.220.651.410.921.140.481.220.601.481.08
 48 months1.330.681.470.961.120.421.210.541.390.78
 10 years1.290.801.350.901.150.481.571.201.591.37
 20 years1.280.831.340.871.130.471.140.481.210.63
 N%N%N%N%N%
Use of antipsychotics          
 Baseline15286.98287.23172.11560.03186.1
 6 months14884.66367.02455.8936.02055.6
 24 months13679.53739.41841.9416.71440.0
 48 months12270.13234.01023.3416.01233.3
 10 years14287.13440.0820.0626.1725.9
 20 years11781.83036.11025.0420.01037.0
Illness pattern over 20 years          
 Single episode10.61011.4819.0417.41038.5
 Multiple episodes4325.37079.52866.71356.5830.8
 Continuous illness12674.189.1614.3626.1830.8
a
For the apathy-asociality, inexpressivity, reality distortion, and disorganization scales, zero indicates no symptoms; the depression scale ranges from 9 (no symptoms) to 27; the mania/excitement scale ranges from 1 (none) to 7 (very severe). Ns were 153, 148, 145, 166, and 175 for the schizophrenia group for 6-month to 20-year waves, respectively, 83, 81, 82, 86, and 94 for the bipolar disorder with psychosis group, 38, 41, 40, 41, and 43 for the psychotic depression group, 26, 28, 23, 29, and 36 for the substance-induced psychosis group, and 23, 23, 21, 23, and 25 for the other/undetermined psychoses group. GAF=Global Assessment of Functioning.
Next, we tested the significance of changes within the three groups from month 6 to each follow-up wave (Figure 1). GAF scores remained stable or improved from month 6 through month 48 for each group, but thereafter they declined by 13 points in the schizophrenia group and 9 points in the other groups. With regard to specific symptom dimensions, apathy-asociality also remained stable or improved through month 48 but then worsened (Cohen’s d values, 0.35–0.73, comparing year 20 to month 6). Inexpressivity improved through year 10, but by year 20 it returned to initial levels. Reality distortion symptoms were at stable low levels throughout the follow-up period in the psychotic mood disorders and other psychoses groups. In the schizophrenia group, reality distortion ratings were stable through month 48 but then increased substantially (d=0.45), whereas disorganization worsened even more (d=0.61). These increases are particularly notable given that rates of antipsychotic medication use remained largely stable in the schizophrenia group, while they declined dramatically in the other groups (see Figure S1 in the data supplement). In contrast, depression ratings decreased and mania/excitement ratings remained stable across the interval.
FIGURE 1. Outcomes in Major Diagnostic Groups in a Study of Psychotic Disorders Over the Two Decades Following First Hospitalization: Mean Ratings at Each Follow-Up and Comparison With Month 6a
a Ns were 153, 148, 145, 166, and 175 for the schizophrenia group at the 6-month to 20-year waves, respectively, 121, 122, 122, 127, and 137 for the mood disorders with psychosis group, and 49, 51, 44, 52, and 61 for the other psychoses group. Significant findings are indicated for the comparison with month 6.
*p<0.01.
We also compared clinical course among disorders, focusing on the initial outcome (month 6), the long-term outcome (year 20), and the change between these waves (see Table S1 in the data supplement). Compared with the mood disorders with psychosis group, the schizophrenia group had consistently worse outcomes on the GAF and in ratings for apathy-asociality, inexpressivity, reality distortion, and disorganization. Moreover, worsening was greater in the schizophrenia group than in the psychotic mood disorders group on these outcomes, except for inexpressivity. No differences were observed between disorder groups on depression and mania/excitement. The only difference between the other psychoses group and the psychotic mood disorders group was higher ratings in the former on reality distortion symptoms at year 20.
Although highly accurate, 10-year diagnosis may be confounded by illness course during the first decade. To consider the impact of this potential confounding, we repeated the analyses using 6-month diagnosis (see Figure S2 in the data supplement). Schizophrenia trajectories were virtually unchanged on the GAF and on ratings for apathy-asociality, inexpressivity, reality distortion, and disorganization. Trajectories of the psychotic mood disorders and other psychoses groups were more severe using 6-month diagnoses compared with 10-year diagnoses. This pattern is consistent with misclassification, that is, that some patients who followed a schizophrenia trajectory were assigned other diagnoses at month 6. Indeed, we previously found that many 6-month nonschizophrenia cases in this cohort were later reclassified as schizophrenia, whereas few patients were reclassified from schizophrenia to other diagnoses (17). The reanalysis with 6-month diagnosis had little impact on trajectories of mood symptoms.

Trajectories of Diagnostic Groups

Next, we used multilevel spline regression to estimate trajectories for the three groups across the entire follow-up period for each outcome. The number of segments was determined empirically (see Table S2 in the data supplement). Selected models either were linear (i.e., had only one segment) or were allowed one change in the trajectory’s slope (i.e., had two segments). Estimated trajectories (Figure 2) closely resembled longitudinal patterns obtained by smoothing raw data (see Figure S3 in the data supplement), which suggests that the models represented the data well. Table 3 lists magnitude of change in symptom scores per year (unadjusted columns).
FIGURE 2. Trajectories of Diagnostic Groups Over the Two Decades Following First Hospitalization, Modeled Using Spline Regressiona
a Ns are 175 for the schizophrenia group, 137 for the mood disorders with psychosis group, and 61 for the other psychoses group.
TABLE 3. Changes in Symptoms Over Time in a Study of Psychotic Disorders Over the Two Decades Following First Hospitalization: Unadjusted and Adjusted for Age and Antipsychotic Medicationsa
Measure and VariableSchizophrenia Group (N=175)Mood Disorders With Psychosis Group (N=137)Other Psychoses Group (N=61)
UnadjustedAdjustedUnadjustedAdjustedUnadjustedAdjusted
BpBpBpBpBpBp
GAF            
 Time (S1)–0.70<0.001–0.59<0.0011.52<0.0011.26<0.0010.490.1190.600.097
 Time (S2)–0.98<0.001–0.94<0.001–0.99<0.001–0.600.011
 Age–0.100.231–0.070.415–0.310.055
 Antipsychotics–0.840.480–4.78<0.001–5.190.004
Apathy-asociality            
 Time (S1)0.34<0.0010.26<0.001–0.59<0.001–0.58<0.0010.22<0.0010.050.571
 Time (S2)  0.48<0.0010.40<0.001
 Age0.090.1330.090.0140.160.045
 Antipsychotics2.590.0012.33<0.0011.900.058
Inexpressivity            
 Time (S1)–0.51<0.001–0.55<0.001–0.45<0.001–0.290.0190.120.0350.110.245
 Time (S2)0.27<0.0010.320.0020.23<0.0010.21<0.001
 Age0.000.957–0.020.4530.010.912
 Antipsychotics2.590.0032.04<0.0011.980.035
Reality distortion            
 Time0.18<0.0010.200.003–0.020.102–0.040.0560.030.299–0.040.553
 Age–0.020.6790.020.1240.070.208
 Antipsychotics–1.820.0270.540.0202.240.001
Disorganization            
 Time0.18<0.0010.180.0010.07<0.0010.050.0640.110.0010.030.602
 Age–0.010.8750.020.3930.070.146
 Antipsychotics–1.650.0050.000.990–0.050.939
Depression            
 Time (S1)–0.10<0.001–0.080.016–0.990.001–0.890.002–0.060.065–0.150.007
 Time (S2)0.030.1660.000.969
 Age–0.020.4660.040.1300.080.056
 Antipsychotics0.720.0880.830.0331.490.019
Mania/excitement            
 Time0.000.3130.010.1490.000.6960.000.8870.000.889–0.010.368
 Age–0.010.2910.000.5490.010.332
 Antipsychotics–0.200.0090.090.2290.020.896
a
B=change in symptom score per year; GAF=Global Assessment of Functioning; dashes indicate nonapplicable (i.e., effects not included in the model). S1 is first segment of the 20-year interval or the entire interval if the model has only one segment, and S2 is the second segment. The transition point between segments for the GAF was at year 5 for the mood disorders with psychosis group and at year 7 for the other psychoses group; for apathy-asociality, it was at year 7 for the mood disorders with psychosis group; for inexpressivity, it was at year 6 for the mood disorders with psychosis group and at year 7 for the schizophrenia group; for depression, it was at year 2 for the mood disorders with psychosis group. Effects with p values <0.01 were considered significant.
GAF score declined significantly in the schizophrenia group; it improved initially in the psychotic mood disorders group and the other psychoses group but declined significantly after approximately year 7 (Figure 2). Apathy-asociality ratings worsened in all groups, although in the psychotic mood disorders group it improved through about year 7 and then deteriorated well beyond the initial level. Inexpressivity lessened until approximately year 7 but increased thereafter, except in the other psychoses group, where the trajectory was flat throughout. Reality distortion ratings increased in the schizophrenia group but remained stable in the other groups. Disorganization ratings worsened in all groups. Depression ratings improved in all groups, but in the psychotic mood disorders group, improvement plateaued at year 2. Mania/excitement ratings did not change significantly across the interval. Changes in GAF score were primarily driven by changes in apathy-asociality and reality distortion ratings (see Table S3 in the data supplement).
To test whether the observed patterns reflect effects of aging or changes in treatment rather than illness evolution, we repeated the analyses controlling for age and antipsychotic use at each assessment point (Table 3). Age had no effect on psychopathology after accounting for time since baseline. Antipsychotic use was associated with worse GAF scores, inexpressivity ratings, and apathy-asociality ratings overall, but with lower disorganization and mania/excitement ratings in the schizophrenia group. Also, antipsychotic use was associated with lower reality distortion ratings in the schizophrenia group, but greater symptom ratings in the other psychoses group. This pattern may indicate medication side effects or selection effects (for example, sicker participants are more likely to receive long-term treatment with antipsychotics). Adjustment for these two variables did not change the findings for illness trajectories except that three slopes became nonsignificant in the other psychoses group and two became nonsignificant in the psychotic mood disorders group. Adjustments for various other potential confounders had little impact on the pattern of results (see the Supplementary Results section and Table S4 in the data supplement).

Discussion

We found that schizophrenia exhibits substantial and consistent decline over the two decades following first hospitalization. The mean GAF score for this group decreased from 49 at the 6-month assessment to 36 at the 20-year assessment, and the latter score indicates impairment in reality testing, communication, or pervasive disability. With regard to specific symptom dimensions, worsening was observed in ratings for apathy-asociality, reality distortion, and disorganization. Initially, the psychotic mood disorders group was less severely ill than the schizophrenia group (a mean GAF score of 65 at 6 months), but the psychotic mood disorders group also showed worsening in GAF score and ratings for apathy-asociality and disorganization. This decline was smaller (9 points on the GAF) than that in schizophrenia. The decline began 5 to 8 years after the first hospitalization. Depression and mania ratings showed no signs of worsening in any of the disorder groups.
Overall, 74% of participants in the schizophrenia group were continuously ill, compared with 14% in the psychotic mood disorders group, and the majority of other patients in the two groups experienced multiple episodes during the 20-year interval.
Our results align with the Kraepelinian view of schizophrenia as following a downward trajectory. The illness worsened gradually, but in the second decade the decline become noticeable. Treatment initiation improved reality distortion and disorganization substantially, as indicated by change from baseline to month 6, but symptoms gradually returned, undoing many treatment gains by year 20. Contrary to Kraepelin’s observations, participants in the mood disorders with psychosis group also experienced significant worsening, although it was less pronounced than worsening in the schizophrenia group, and it was limited to negative symptoms (reality distortion and disorganization ratings remained low). Of note, mood symptoms showed a different pattern, either improving or remaining consistently low.
Heterogeneity within diagnostic groups was substantial, and many participants achieved good outcomes (i.e., GAF score >60 at year 20): 42% in the mood disorders with psychosis group, 31% in the other psychoses group, and 4% in the schizophrenia group. We previously reported (11) that rank-order stability over 20 years is modest for negative symptoms (test-retest r values, ∼0.40) and low for reality distortion and disorganization (r values, ∼0.20). Thus, trajectories of individual participants varied around the mean trend for their group, with some increasing and others decreasing.
To minimize misclassification, which is a common problem early in the course of psychosis (17), we used consensus diagnoses based on 10 years of observation. Such diagnoses are very accurate but are influenced by illness course. To examine this potential confounding, we repeated the analyses using 6-month diagnoses. This had little impact on trajectories for schizophrenia, other than moderating the increase in psychotic symptom severity somewhat. In contrast, other disorders looked consistently worse when 6-month diagnoses were used. This pattern can be explained by initial misclassification of schizophrenia cases as nonschizophrenia psychoses. Nevertheless, illness course is integral to diagnostic criteria (e.g., 6 months of symptoms are required for schizophrenia diagnosis), and some circularity is inherent in comparing course of diagnostic groups.
Trajectories of reality distortion were notable in that symptoms worsened in schizophrenia, despite consistently high rates of antipsychotic medication use across the two decades (∼80% at each wave). This pattern is consistent with suggestions that antipsychotics may lose some of their effectiveness in the long term and may even lead to paradoxical effects (27, 28), perhaps as a result of nonadherence and relapses (29). Also, changes in the medications prescribed or their dosages may contribute to this finding. Our study cannot directly test these possibilities, as they require an experimental design.
The present findings paint a bleaker picture than the DOSMeD study did; in that study, only 29% of participants with schizophrenia were continuously ill and more than half had GAF scores >60 after two decades (7). A variety of factors distinguish the United States from the other countries included in the DOSMeD study (India, Russia, Japan, England, Ireland, and the Czech Republic). Availability of family support and community integration may contribute to differences in outcomes (8), but a particularly salient issue is access to treatment. The Suffolk County, New York, cohort received community services typical of the United States and experienced a substantial unmet need for care (30), which may account for poor outcomes, especially compared with countries that have universal health care.
On the other hand, our results are consistent with meta-analyses that found outcome in schizophrenia to be almost universally poor (31, 32). Moreover, a systematic review of first-episode psychosis studies found that during the first decade of illness, outcomes in treatment studies (which had a mean GAF score of 66) were much better than in observational studies (a mean GAF score of 50), and the latter outcomes are consistent with initial outcomes in the present cohort. The present study extends these reviews by documenting the timing and pace of decline across multiple symptom dimensions.
Our findings are also consistent with evidence of accelerated neurodegeneration in schizophrenia (33) that may underpin worsening negative symptoms. Poor physical health also may contribute to worse clinical course, as it limits daily functioning, impairs cognitive performance, and is common in psychotic disorders (34). We observed significant effects of poor health in the psychotic mood disorders group but not in the other groups (see Table S4 in the data supplement). Furthermore, our results for the psychotic mood disorders group are consistent with studies that reported functional impairment and residual symptoms to be common in psychotic bipolar disorder years after first admission (35).
These results should not be interpreted as an indication that good outcomes are out of reach. There is extensive evidence that aggressive treatment, especially psychotherapy and vocational rehabilitation, can substantially improve outcomes (3638). Moreover, 10-year follow-up studies of first-episode psychosis in Denmark and the United Kingdom, countries with universal access to psychiatric services, found relatively good outcomes with no evidence of decline and few continuously ill participants both in schizophrenia and nonschizophrenia groups (5, 6). It is possible that with better care, outcomes in the United States would mirror those of Denmark and the United Kingdom.
This study has several limitations. First, it is limited to one geographic location and does not necessarily reflect illness course in other regions or health care systems. Nevertheless, the findings call attention to a glaring public health problem in the United States. Second, attrition was nonnegligible; 32% of survivors could not be contacted or declined participation. However, our attrition analyses suggest that the nonparticipants were largely similar to the participants, except for a slightly higher likelihood of being in a minority group and of having severe psychotic symptoms at baseline, both of which are risk factors for worse outcomes (29, 39). Thus, our results may underestimate severity of clinical course. Third, assessments began at first admission rather than first onset of symptoms. Fortunately, duration of preadmission illness was short relative to the follow-up, with a median duration of untreated psychosis of 40 days (only 27% were ill for more than a year). Fourth, we did not measure mania symptoms dimensionally and had to rely on a proxy measure, the excitement rating of the BPRS. Fifth, the study focused on symptoms and global outcome and did not consider dimensions of functioning. Functioning was beyond the scope of the present study, but we are reporting several functional outcomes in another article (40).
Our results suggest an alarming public health problem, namely, a high symptom burden in psychotic disorders that increases with time and ultimately may undo initial treatment gains. Previous studies have suggested that better care may preempt this decline. In the United States, psychotic disorders are associated with a large unmet need for care, and the present study highlights this shortcoming as an urgent priority. Reasons for the decline are unclear, and numerous explanations are possible. Greater research attention to the middle and late course of psychotic disorders is needed to identify factors that drive this decline, as it unfolds, and to inform the field on how to preempt it.

Acknowledgments

The authors gratefully acknowledge the support of the participants and mental health community of Suffolk County for contributing their time and energy to this project. They are also indebted to the study coordinators for their dedicated efforts, the interviewers for their careful assessments, and the psychiatrists who derived the consensus diagnoses. Special thanks to Janet Lavelle for her many contributions to the study.

Supplementary Material

File (appi.ajp.2017.16101191.ds001.pdf)

References

1.
Kraepelin E: Psychiatrie: Ein Lehrbuch, 6th ed. Leipzig, Germany, Barth, 1899
2.
McGlashan TH: A selective review of recent North American long-term followup studies of schizophrenia. Schizophr Bull 1988; 14:515–542
3.
Zipursky RB, Reilly TJ, Murray RM: The myth of schizophrenia as a progressive brain disease. Schizophr Bull 2013; 39:1363–1372
4.
Menezes NM, Arenovich T, Zipursky RB: A systematic review of longitudinal outcome studies of first-episode psychosis. Psychol Med 2006; 36:1349–1362
5.
Austin SF, Mors O, Budtz-Jørgensen E, et al: Long-term trajectories of positive and negative symptoms in first episode psychosis: a 10-year follow-up study in the OPUS cohort. Schizophr Res 2015; 168:84–91
6.
Morgan C, Lappin J, Heslin M, et al: Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychol Med 2014; 44:2713–2726
7.
Harrison G, Hopper K, Craig T, et al: Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry 2001; 178:506–517
8.
Hopper K, Harrison G, Wanderling J: An overview of course and outcome in ISoS, in Recovery From Schizophrenia: An International Perspective: A Report From the WHO Collaborative Project, the International Study of Schizophrenia. Edited by Hopper K, Harrison G, Janca A, et al. New York, Oxford University Press, 2007, pp 23–38
9.
Harrow M, Grossman LS, Jobe TH, et al: Do patients with schizophrenia ever show periods of recovery? A 15-year multi-follow-up study. Schizophr Bull 2005; 31:723–734
10.
Blanchard JJ, Cohen AS: The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull 2006; 32:238–245
11.
Kotov R, Foti D, Li K, et al: Validating dimensions of psychosis symptomatology: neural correlates and 20-year outcomes. J Abnorm Psychol 2016; 125:1103–1119
12.
Liddle PF: The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry 1987; 151:145–151
13.
Cuesta MJ, Peralta V: Integrating psychopathological dimensions in functional psychoses: a hierarchical approach. Schizophr Res 2001; 52:215–229
14.
Van Os J, Gilvarry C, Bale R, et al: A comparison of the utility of dimensional and categorical representations of psychosis. UK700 Group. Psychol Med 1999; 29:595–606
15.
McGrath J: Dissecting the heterogeneity of schizophrenia outcomes. Schizophr Bull 2008; 34:247–248
16.
Bromet EJ, Schwartz JE, Fennig S, et al: The epidemiology of psychosis: the Suffolk County Mental Health Project. Schizophr Bull 1992; 18:243–255
17.
Bromet EJ, Kotov R, Fochtmann LJ, et al: Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 2011; 168:1186–1194
18.
Andreasen NC: The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
19.
Andreasen NC: The Scale for the Assessment of Positive Symptoms. Iowa City, University of Iowa, 1984
20.
Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799–812
21.
Spitzer RL, Williams JB, Gibbon M, et al: The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 1992; 49:624–629
22.
Jablensky A, Sartorius N, Ernberg G, et al: Schizophrenia: manifestations, incidence, and course in different cultures: a World Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20:1–97
23.
Kotov R, Leong SH, Mojtabai R, et al: Boundaries of schizoaffective disorder: revisiting Kraepelin. JAMA Psychiatry 2013; 70:1276–1286
24.
Klein DN, Kotov R: Course of depression in a 10-year prospective study: evidence for qualitatively distinct subgroups. J Abnorm Psychol 2016; 125:337–348
25.
Muggeo VMR: Estimating regression models with unknown break-points. Stat Med 2003; 22:3055–3071
26.
Burnham KP, Anderson DR: Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach, 2nd ed. New York, Springer-Verlag, 2002
27.
Harrow M, Jobe TH: Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophr Bull 2013; 39:962–965
28.
Wunderink L, Nieboer RM, Wiersma D, et al: Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013; 70:913–920
29.
Carbon M, Correll CU: Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci 2014; 16:505–524
30.
Mojtabai R, Fochtmann L, Chang SW, et al: Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study. Schizophr Bull 2009; 35:679–695
31.
Hegarty JD, Baldessarini RJ, Tohen M, et al: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409–1416
32.
Jääskeläinen E, Juola P, Hirvonen N, et al: A systematic review and meta-analysis of recovery in schizophrenia. Schizophr Bull 2013; 39:1296–1306
33.
Fusar-Poli P, Smieskova R, Kempton MJ, et al: Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 2013; 37:1680–1691
34.
DE Hert M, Correll CU, Bobes J, et al: Physical illness in patients with severe mental disorders, I: prevalence, impact of medications, and disparities in health care. World Psychiatry 2011; 10:52–77
35.
Treuer T, Tohen M: Predicting the course and outcome of bipolar disorder: a review. Eur Psychiatry 2010; 25:328–333
36.
Alvarez-Jiménez M, Parker AG, Hetrick SE, et al: Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull 2011; 37:619–630
37.
Hegelstad WT, Larsen TK, Auestad B, et al: Long-term follow-up of the TIPS early detection in psychosis study: effects on 10-year outcome. Am J Psychiatry 2012; 169:374–380
38.
Kane JM, Robinson DG, Schooler NR, et al: Comprehensive versus usual community care for first-episode psychosis: 2-year outcomes from the NIMH RAISE early treatment program. Am J Psychiatry 2016; 173:362–372
39.
Morgan C, Charalambides M, Hutchinson G, et al: Migration, ethnicity, and psychosis: toward a sociodevelopmental model. Schizophr Bull 2010; 36:655–664
40.
Velthorst E, Fett AK, Reichenberg A, et al: The 20-year longitudinal trajectories of social functioning in individuals with psychotic disorders. Am J Psychiatry 2017; 174:1075–1085

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1064 - 1074
PubMed: 28774193

History

Received: 28 October 2016
Revision received: 24 April 2017
Accepted: 1 May 2017
Published online: 4 August 2017
Published in print: November 01, 2017

Keywords

  1. Psychosis
  2. Epidemiology
  3. Outcome Studies
  4. Bipolar Disorder Longitudinal
  5. First Episode

Authors

Details

Roman Kotov, Ph.D. [email protected]
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Laura Fochtmann, M.D., M.B.I.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Kaiqiao Li, M.S.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Marsha Tanenberg-Karant, M.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Eduardo A. Constantino, M.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Joan Rubinstein, M.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Greg Perlman, Ph.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Eva Velthorst, Ph.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Anne-Kathrin J. Fett, Ph.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Gabrielle Carlson, M.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.
Evelyn J. Bromet, Ph.D.
From the Department of Psychiatry, Stony Brook University, Stony Brook, N.Y.; the Department of Psychiatry and the Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York; the Department of Educational Neuroscience and Research Institute LEARN, Faculty of Psychology and Education, VU University, Amsterdam; and the Department of Psychosis Studies, Institute of Psychiatry, King’s College London.

Notes

Address correspondence to Dr. Kotov ([email protected]).

Competing Interests

Dr. Constantino has served on the speakers bureau for Janssen Pharmaceuticals. The other authors report no financial relationships with commercial interests.

Funding Information

National Institutes of Health10.13039/100000002: MH094398, MH44801
Eli Lilly Corporation:
Stanley Medical Research Institute10.13039/100007123:
Supported by NIH grants MH44801 (to Dr. Bromet) and MH094398 (to Dr. Kotov); by a grant from Eli Lilly (to Dr. Bromet), and by a grant from the Stanley Medical Research Institute (to Dr. Bromet).

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share